Search Results - "Bebernitz, Gregory"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
  2. 2

    Avoidance of the Ames test liability for aryl–amines via computation by McCarren, Patrick, Bebernitz, Gregory R., Gedeck, Peter, Glowienke, Susanne, Grondine, Melissa S., Kirman, Louise C., Klickstein, Jacob, Schuster, Herbert F., Whitehead, Lewis

    Published in Bioorganic & medicinal chemistry (15-05-2011)
    “…Aryl–amines are commonly used synthons in modern drug discovery, however a minority of these chemical templates have the potential to cause toxicity through…”
    Get full text
    Journal Article
  3. 3

    The Effect of 1,3-Diaryl-[1H]-pyrazole-4-acetamides on Glucose Utilization in ob/ob Mice by Bebernitz, Gregory R, Argentieri, Greg, Battle, Beverly, Brennan, Christine, Balkan, Bork, Burkey, Bryan F, Eckhardt, Michele, Gao, Jiaping, Kapa, Prasad, Strohschein, Robert J, Schuster, Herbert F, Wilson, Mary, Xu, David D

    Published in Journal of medicinal chemistry (02-08-2001)
    “…This article provides evidence of a new class of compounds, 1,3-diaryl-[1H]-pyrazole-4-acetamides, initially identified from their ability to increase glucose…”
    Get full text
    Journal Article
  4. 4

    The impact of fatty acid oxidation on energy utilization: targets and therapy by Bebernitz, Gregory R, Schuster, Herbert F

    Published in Current pharmaceutical design (01-06-2002)
    “…Utilization of fat as a long-term energy storage vehicle is crucial for the maintenance of cellular metabolism and is under intricate and many times redundant…”
    Get more information
    Journal Article
  5. 5
  6. 6
  7. 7

    Reduction in Glucose Levels in STZ Diabetic Rats by 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid:  A Prodrug Approach for Targeting the Liver by Bebernitz, Gregory R, Dain, Jeremy G, Deems, Rhonda O, Otero, Dario A, Simpson, W. Ronald, Strohschein, Robert J

    Published in Journal of medicinal chemistry (15-02-2001)
    “…The overproduction of glucose by the liver in NIDDM patients markedly contributes to their fasting hyperglycemia and is a direct consequence of the increased…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Hypoglycemic Prodrugs of 4-(2,2-Dimethyl-1-oxopropyl)benzoic Acid by Aicher, Thomas D, Bebernitz, Gregory R, Bell, Philip A, Brand, Leonard J, Dain, Jeremy G, Deems, Rhonda, Fillers, William S, Foley, James E, Knorr, Douglas C, Nadelson, Jeffrey, Otero, Dario A, Simpson, Ronald, Strohschein, Robert J, Young, Douglas A

    Published in Journal of medicinal chemistry (14-01-1999)
    “…SAH 51-641 (1) is a potent hypoglycemic agent, which acts by inhibiting hepatic gluconeogenesis. It is a prodrug of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid…”
    Get full text
    Journal Article
  10. 10

    Hepatic glycogen cycling contributes to glucose lowering effects of the glucokinase activator LCZ960 by Laurent, Didier, Yerby, Brittany, Zhang, Bailin, Chen, Xiao-Hui, Gounarides, John, Zhang, JieL, Gao, Jiaping, Bebernitz, Gregory, Duttaroy, Alokesh

    Published in European journal of pharmacology (05-09-2013)
    “…Glucokinase (GK) acts as a glucose sensor by facilitating glucose phosphorylation into glucose-6-phosphate (G6P) in the liver and pancreas, the two key target…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14